Quotient Investors’s Gilead Sciences GILD Stock Holding History

Quotient Investors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-14,832	Closed	-$1.01M	–	166
2017 Q1	$1.01M	Sell	14,832 -9,655	-39%	-$679K	0.61%	54
2016 Q4	$1.75M	Buy	24,487 +16,300	+199%	+$1.21M	1.1%	30
2016 Q3	$648K	Buy	+8,187	New	+$665K	0.42%	85
2016 Q1	–	Sell	-21,018	Closed	-$2.13M	–	223
2015 Q4	$2.13M	Sell	21,018 -2,428	-10%	-$253K	0.82%	43
2015 Q3	$2.3M	Sell	23,446 -30,048	-56%	-$3.34M	0.51%	56
2015 Q2	$6.26M	Buy	53,494 +9,700	+22%	+$1.06M	0.86%	35
2015 Q1	$4.3M	Buy	43,794 +9,000	+26%	+$914K	0.58%	50
2014 Q4	$3.28M	Buy	+34,794	New	+$3.6M	0.67%	48

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quotient Investors's GILD Position: Q2 2017 in Review

Quotient Investors sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 14,832 shares — an estimated $1.01M sold.

Quotient Investors first reported a position in GILD in Q4 2014 and held it in 8 quarters. The position peaked at $6.26M in Q2 2015. 1,520 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

Quotient Investors reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
Quotient Investors sold 14,832 Gilead Sciences shares in Q2 2017, an estimated $1.01M.
Quotient Investors first reported a position in Gilead Sciences in Q4 2014 and held it in 8 quarters.
Quotient Investors's Gilead Sciences position peaked at $6.26M in Q2 2015.
1,520 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Quotient Investors's 13F filing for Q2 2017, filed 20 Jul 2017.